PROTACs: Data in ER+/HER2- MBC

CME

PROTAC ER Degraders in ER+/HER2- MBC After ET: Novel ER-Targeting Therapy Data and a Look to the Future

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: November 14, 2024

Expiration: April 13, 2025

Erika P. Hamilton
Erika P. Hamilton, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In the phase I/II VERITAC trial with vepdegestrant ± palbociclib for ER+/HER2- advanced breast cancer, a median PFS of >11 months was reported in which of the following patient populations?